Moon Eun-Sang – CEO, SillaJen – South Korea
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
Address: 18th Floor, Hanjin Main Bld, 118, Namdaemunno-2-ga, Seoul,Republic of Korea
Tel: +82 2 772 4000
With more than thirty years of experience as one of Republic of Korea’s premiere full-service law firms, Lee & Ko has a widely recognized and long-established record of excellence in providing expert legal advice and representation to its diverse clientele in domestic and international matters involving all areas of legal practice. ith a wealth of experience in virtually all aspects of corporate law practice, Lee & Ko continues to be a highly regarded leader among Republic of Korean law firms in providing excellent legal services and creative approaches to both domestic and foreign clients doing business in or with Republic of Korea. With some of Republic of Korea’s most experienced and capable corporate law practitioners among its partners and associates, Lee & Ko’s clients receive the highest quality, the most efficient, and the most innovative legal assistance available. Lee & Ko has a distinguished and well-deserved reputation for consistently providing timely, up-to-date, accurate and reliable legal assistance with all manner of corporate legal matters, including incorporation and registration, corporate governance issues and the issuance of corporate securities.
In addition, Lee & Ko has one of Republic of Korea’s most capable, versatile and extensive legal practices in domestic and cross-border mergers and acquisitions. Lee & Ko has served as key legal counsel for innumerable foreign and domestic clients in connection with a broad range of highly complex and sensitive transactions, particularly in recent decades as the Republic of Korean corporate landscape has become more international and complex.
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation…
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Tom Roberts came to UCB Korea following a position at the company’s Japanese affiliate in late 2011. He describes the market conditions for UCB’s specialty products and emphasizes the importance…
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Chung Seung, Minister of Food and Drug Safety, discusses the latest improvements to Korea’s regulatory system and highlights vaccines, biosimilars and stem cell research as key components of the country’s…
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Janssen’s managing director in Korea discusses the groups long and significant commitment to R&D in the country, as well as some of the challenges that one of the most innovative…
The founder of MEDIPOST, the producer of the only approved allogenic stem cell product in the world, disucsses their development goals for the coming years and the potential for regenerative…
Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the…
After a lengthy career at Novartis, Angie Kim recently started working at BMS Korea to develop the affiliate. She discusses diversifying the company’s portfolio and their footprint in Korea as…
Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers?…
See our Cookie Privacy Policy Here